The primary objective of the Imaging and Radiation Oncology (IROC) Group is to provide scientific and technical expertise for incorporation of appropriate, integrated quality Assurance (QA) and image data management for both imaging and radiotherapy (RT) in applicable trials conducted by the National Clinical Trials Network (NCTN) Program and other NCI funded clinical trial groups (NCORP and ETCTN). The physical IROC QA Centers are distributed in 4 main locations and are administratively organized through the American College of Radiology (ACR). The QA Centers include IROC Houston, IROC Ohio, IROC Rhode Island, and IROC Philadelphia. The Advanced Technology QA Center (ATC) located at Washington University, St. Louis will provide their expertise and consultation services to IROC as needed. IROC capitalizes on existing infrastructure and expertise at QA centers currently providing services to the NCI?s clinical trial programs. Work flows, processes and information systems have been enhanced taking into account the best practices and standards in an integrated vision across NCI?s clinical trials. The interdependencies between imaging and RT are synergized eliminating duplication of services and optimizing efficient and effective workflows. A major strength of IROC is the development of consistent standard operating procedures for all imaging and RT aspects of the NCTN, NCORP and ETCTN (NCI Groups) and to facilitate a seamless flow of imaging and RT patient case datasets across the networks. IROC?s organizational structure allows the delivery of a broad array of imaging and RT QA services including Site Qualification; Trial Design Support; Credentialing; Data Management (Pre- and Post-treatment Case Review); and Case Review. An information technology infrastructure is used that harmonizes IROC services, data collection, assessment and management for the NCI Groups? clinical trials. IROC implements programs that assure consistent high quality imaging and RT planning/delivery across the NCTN participating sites. IROC members collaborate with the NCI, NCI Groups, and disease/modality committees within each Network Group to provide an optimum and effective imaging and RT core service. The IROC Group will analyze QA data obtained prospectively/retrospectively and the correlation it might have with clinical trial outcomes to better determine and prioritize appropriate QA activities that maximize their benefit to clinical trials.

Public Health Relevance

Today?s cancer trials frequently require the use of imaging and/or radiation therapy to achieve the most effective treatment. Rigorous QA of these methodologies secures consistency across participating sites by managing potential variability which would otherwise obscure true therapeutic outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA180803-08
Application #
10114976
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-05-26
Project End
2025-02-28
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
8
Fiscal Year
2021
Total Cost
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Glenn, Mallory C; Hernandez, Victor; Saez, Jordi et al. (2018) Treatment plan complexity does not predict IROC Houston anthropomorphic head and neck phantom performance. Phys Med Biol 63:205015
Videtic, Gregory M; Paulus, Rebecca; Singh, Anurag K et al. (2018) Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys :
Monroe, James I; Boparai, Karan; Xiao, Ying et al. (2018) NRG Oncology medical physicists' manpower survey quantifying support demands for multi-institutional clinical trials. Pract Radiat Oncol 8:324-331
Steinmann, Angela; Stafford, R Jason; Sawakuchi, Gabriel et al. (2018) Developing and characterizing MR/CT-visible materials used in QA phantoms for MRgRT systems. Med Phys 45:773-782
Men, Kuo; Boimel, Pamela; Janopaul-Naylor, James et al. (2018) Cascaded atrous convolution and spatial pyramid pooling for more accurate tumor target segmentation for rectal cancer radiotherapy. Phys Med Biol 63:185016
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
FitzGerald, Thomas J; Bishop-Jodoin, Maryann (2018) Hodgkin Lymphoma: Differences in Treatment Between Europe and the United States/North America: Evolving Trends in Protocol Therapy. Clin Med Insights Oncol 12:1179554918754885
Lewis, Dana J; Taylor, Paige A; Followill, David S et al. (2018) A New Anthropomorphic Pediatric Spine Phantom for Proton Therapy Clinical Trial Credentialing. Int J Part Ther 4:20-27
Lukka, Himanshu R; Pugh, Stephanie L; Bruner, Deborah W et al. (2018) Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys 102:287-295
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726

Showing the most recent 10 out of 87 publications